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Abstract 
 
Biomarker detection in 
Bisphosphonate-related Osteonecrosis of the Jaw 
Jin-Woo Kim 
Department of Dental Science 
The Graduate School, Yonsei University 
 
Various bone biomarkers have been suggested for the risk assessment for 
osteonecrosis of the jaw, an oral complication associated with bisphosphonate (BP) 
use; however, no consensus has been established. The aim of this thesis was to 
investigate a possible biomarker for bisphosphonate-related osteonecrosis of the jaw 
(BRONJ) in an animal model.  
Forty eight Sprague-Dawley rats were randomly divided into the two groups; 
bisphosphonate group (n=36) treated with weekly zoledronic acid injection and 
control group (n=12) treated with weekly saline injection. After 6 weeks, surgical 
intervention was performed, and weekly injections were continued up to 8 weeks. Rats 
in the bisphosphonate group were then further classified to the ONJ group and the 
non-ONJ group, and biomarkers, including serum CTx, Glu-OC, TRACP 5b, 
RANKL, and OPG, were assessed at baseline (T0), at surgical intervention (T1; 8 
weeks) and at sacrifice (T2; 14 weeks). Histomorphometric analysis for quantification 
of osteoclasts was performed.  
TRACP 5b levels and the RANKL/OPG ratio were significantly decreased 
over time in the ONJ group compared to the non-ONJ group (P < 0.05). At T2, the 
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area under the curve was 0.807 for TRACP 5b (sensitivity: 88.9%, specificity 66.7% 
at cutoff) and 0.765 for the RANKL/OPG ratio (sensitivity: 77.8%, specificity 62.9% 
at cutoff). TRACP 5b showed a lower least significant change (LSC; 29.6%) with 
lower intra-assay coefficient variability (CV; 6.32%) and inter-assay CV (11.20%) 
compared to those of the RANKL/OPG ratio (39.27%) and showed a higher signal-to-
noise ratio (2.76) than that of the RANKL/OPG ratio (1.62). Moreover, N.Oc/T.Ar 
and N.Oc/B.Ar demonstrated significantly decreased number of osteoclasts in ONJ 
group versus non-ONJ group. (P < 0.05) 
These results demonstrated that serum TRACP 5b and the RANKL/OPG ratio 
were possible biomarkers for BRONJ. These data may provide useful additional 
information for future ONJ research. Further studies are needed to validate these 
results in humans with ONJ. 
 
 
 
 
 
 
 
 
 
 
 
 
 
---------------------------------------------------------------------------------------------------- 
Keywords: Bisphosphonate; Osteonecrosis of the jaw; Biomarker; Tartrate-resistant 
acid phosphatase; receptor activator of nuclear factor-κβ ligand  
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I. Introduction 
 
Since the first report of osteonecrosis of the jaw (ONJ) associated with 
bisphosphonate administration in 20031, there have been many attempts to establish 
the pathophysiological nature of this disease2,3. Based on the pharmacological effects 
of bisphosphonates on osteoclasts, ONJ has been thought to be associated mainly with 
the oversuppression of bone remodeling2-4. However, still a large part of the diseases 
including appropriate methods for the diagnosis, details of the mechanisms of 
pathogenesis, and effective treatment modalities are still not known.  
Several research groups have attempted to detect biomarkers for ONJ5,6. 
Marx et al.6 performed an uncontrolled retrospective study and found that serum C-
terminal telopeptide of type I collagen (CTx) was a useful predictor of ONJ. However, 
contradictory results were reported in several subsequent clinical studies5,7,8, and no 
conclusive evidence for other bone biomarkers has been published to date9,10. A recent 
position paper published by the American Association of Oral and Maxillofacial 
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surgeons stated that there was no evidence to support the use of currently proposed 
markers11. Given that the increasing global dependence on antiresorptive drugs for 
various bone diseases and the fact that no biomarkers have been validated for 
identifying patients at high risk of developing ONJ, there is an increasing need to 
establish biomarkers of ONJ. 
Osteoclasts, which are thought to be key cells involved in the effects of 
bisphosphonates on ONJ, have two distinct functions: bone resorption and 
maintenance of bone remodeling balance. For measuring the osteoclast-dependent 
bone resorption, collagen-degraded molecules, such as CTx and N-terminal 
telopeptide of type I collagen, have significant roles in several bone diseases, such as 
metabolic, pathologic, and metastatic bone diseases12. Another function, which is 
independent of their resorptive activity, is regulation of the bone remodeling through 
coupling with osteoblasts13-15. This function is thought to be associated with osteoclast 
number and can be reflected by the levels of osteoclast-specific molecules, such as 
tartrate-resistant acid phosphatase isoform 5b (TRACP 5b)16,17. 
Important issue to be considered is that the osteoclast number rather than 
osteoclast activity may mediate the coupling between bone resorption and bone 
formation, which is essential for continuous bone remodeling13,18,19. Previously 
proposed ONJ markers, such as CTx, only reflect the resorptive activity5,12, and the 
role of osteoclasts in bone remodeling is thought to be directly associated with 
bisphosphonate-mediated suppression of bone remodeling in ONJ pathogenesis2,3, 
suggesting that biomarkers reflecting the degree of bone remodeling suppression may 
represent ONJ biomarkers. Hence, the investigator preferentially considered following 
osteoclast-specific markers as ONJ biomarker candidates; TRACP 5b for reflection of 
osteoclast number which is thought to be associated with degree of bone 
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remodeling16,18,19, and circulating RANK/RANKL/OPG system markers as key 
molecules for regulation of osteoclasts function20-23. Analysis also included CTx and 
osteocalcin which had shown controversial clinical results. 
The aim of this thesis was to identify novel biomarkers for ONJ using an 
animal model. Our analysis included the investigation of significant biomarkers for 
ONJ, the assessment of clinical performance of biomarkers, and biological 
interpretation through characterization of histological and radiological features of 
ONJ.  
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II. Materials and Methods 
 
1. Establishment of Animal model and Study design 
Eight-week-old female Sprague-Dawley (SD) rats (n = 48) with a mean 
weight of 220 g (range, 190–247 g), purchased from the Institute of Ewha Medical 
Research, Seoul, Korea (Orient Bio Inc., Seoul, Korea), were used in this study. 
Animals were housed at three rats per cage and were individually numbered using ear 
punches. The cages were placed in a room with filtered air at a temperature of 22 ± 
2°C and 50% ± 10% relative humidity. A 12-h light/dark cycle was maintained. The 
animals were fed a normal rodent diet and water ad libitum. Animals were acclimated 
for 1 week prior to the beginning of the study. This study was approved by and 
performed in accordance with the guidelines of the institutional animal research ethics 
committee.  
The rats were randomly divided into two groups. The bisphosphonate group 
(n = 36) received zoledronic acid (200 μg/kg), and the control group (n = 12) received 
normal saline once a week subcutaneously24,25. Given that the pharmacodynamics of 
bisphosphonates have not been determined in rodents, we determined dosing 
according to the following factors: (1) the oncologically relevant zoledronate doses in 
humans (67 μg/kg/4 weeks); (2) the relatively rapid bone metabolism of rodents; (3) 
the route of bisphosphonate administration; lower plasma concentrations when using 
the subcutaneous route compared to intravenous route; and (4) maximizing drug 
exposure during the relatively short experimental period.  
After 6 weeks of injections, tooth extraction was performed as a surgical 
intervention to induce ONJ. Animals were anesthetized with an intramuscular 
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injection of ketamine (100 mg/kg ketamine, Yuhan Pharmacy, Seoul, Korea), xylazine 
(10 mg/kg Rompun, Bayer AG, Leverkusen, Germany), and meloxicam (1.5 mg/mL 
Metacam, Boehringer Ingelheim, Germany). After syndesmotomy using a sharpened 
dental explorer, adequate luxation was performed until sufficient mobility of the tooth 
was achieved. In this manner, the lower left first to third molars were extracted using 
dental explorer in consecutive order. Gauze pressure was applied to control bleeding, 
and the wounds were left open without any sutures. Weekly injections were continued 
for 8 more weeks, a timeframe chosen according to the pathogenic progression of 
BRONJ11. The animals were then sacrificed for further assessment (Fig. 1). 
 
 
 
 
Figure 1. Study design  
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2. Radiological Assessment 
The ONJ lesion was radiologically assessed by micro-computed tomography 
(µCT, Skyscan 1076, Aartselaar, Belgium). The acquisition settings were at a voxel 
size of 6 µm3 with an X-ray tube voltage of 70 kVp and the intensity current of 140 
µA. An entire region of the mandible (1335 slices; each slice = 8 µm) was scanned for 
each sample. µCT scans revealed the presence of osteolytic lesions accompanied by a 
wide destruction of trabecular patterns with irregular bone margins and sequestrum 
formation in ONJ group. In control group, the extraction socket was nearly filled with 
newly formed bone with normal trabecular patterns. On the other hand, non-ONJ 
group showed insufficient bone fill with osteosclerotic changes of trabecular patterns. 
(Fig. 2) 
 
3. Histological Assessment 
Samples were fixed with 4% phosphate-buffered saline formalin for 2 weeks 
and decalcified in 10% EDTA (pH 7.2) at 4°C for 28 days. Samples were dehydrated 
with a graded series of ethanol, cleaned with xylene, and immersed in paraffin. The 
samples were then embedded in paraffin and cut into 4-μm-thick sections. The 
sections were deparaffinized, rehydrated, and stained with hematoxylin and eosin (H-
E). We determined the presence of ONJ based on histological analysis according to 
the following criteria: (1) presence of an ulcerative lesion with exposed and necrotic 
bone and/or osteolysis, (2) presence of pseudoepitheliomatous-like hyperplasia of the 
epithelium accompanied by inflammatory cell infiltration, and (3) presence of 
sequestrum and bacterial colonies.  
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(a) 
 
(b) 
 
 
 
 
 
 
 
 
Figure 2. Representative clinical and radiological images. 
(a) Non-ONJ group showing normal mucosal healing 8 weeks after surgical 
intervention (b) ONJ occurred group. 
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(c) 
 
 
 
 
 
 
(d) 
 
 
 
 
 
(e) 
 
 
 
 
 
 
(Fig 2. Continued) µCT assessment revealed evident bony healing in control group 
(c) and non-ONJ group (d). Particularly, non-ONJ group showed osteosclerotic 
changes of trabecular patterns with dense woven bone and insufficient bone fill 
compared to control. Typical radiological features of ONJ – osteolytic lesions 
accompanied by a wide destruction of trabecular patterns with irregular bone margins 
and sequestrum – were observed in (e).  
  10 
4. Histomorphometric analysis 
Image capture was carried out using an Eclipse 50i light microscope (Nikon, 
Tokyo, Japan) equipped with CCD camera (MicroPublisher 3.3 RTV cooled, 
QImaging, Bethesda, MD, USA), and Image Pro Capture Kit Platform (Media 
Cybernetics, Bethesda, MD, USA). In a blind-coded fashion, histomorphometric 
evaluation was performed in the 4 to 6 regions of interest (ROI) located at the 
osteonecrosis lesion or prior extraction site with Image Pro Plus 4.5.1 software (Media 
Cybernetics, Bethesda, MD, USA). Measurements included tissue area, (T.Ar, mm2), 
bone area (B.Ar, mm2) and number of osteoclast (N.Oc, #). To normalize indices, 
B.Ar/T.Ar (%), N.Oc/T.Ar (#/mm2) and N.Oc/B.Ar (#/mm2) were calculated for 
further analysis26.  
 
5. Biomarkers Investigation and Statistical Analysis 
For the biomarker investigation, blood samples were obtained after 12 h of 
fasting at time T0 (baseline), T1 (6 weeks; surgical intervention), and T2 (14 weeks; 
sacrifice). Blood samples were collected through the jugular vein (T0, T1) and by 
cardiac puncture (T2) and were then allowed to coagulate for 20 min. Collected serum 
samples were separated by centrifugation (1600 × g for 15 min at 4°C), aliquoted, and 
stored at -70°C until analysis. The concentrations of serum CTx (RatLaps EIA, IDS, 
Boldon, Tyne & Wear, UK), serum undercarboxylated osteocalcin (Glu-OC; Rat Glu-
Osteocalcin high sensitive EIA, Takara Bio, Shiga, Japan), serum TRACP 5b 
(RatTRAP, IDS, Boldon, Tyne & Wear), serum receptor activator of nuclear factor-κβ 
ligand (RANKL; Rat sRANKL ELISA, Cusabio, Wuhan, Hubei, China) and serum 
osteoprotegerin (OPG; Rat sOPG ELISA, Cusabio) were determined in accordance 
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with the manufacturer’s instructions. All marker measurements were performed 
blinded and in duplicates.  
According to the results of histological assessment, rats in the bisphosphonate 
group (n = 36) were further classified into the non-ONJ and ONJ groups. The normal 
distribution and homogeneity of variance for the biomarkers studied (CTx, Glu-OC, 
TRACP 5b, and the RANKL/OPG ratio) were checked before further statistical 
analyses. Overall group differences in biomarkers over time were compared with 
repeated measures analysis of variance (RM-ANOVA). Independent t-tests were used 
to test the significance of differences between the non-ONJ group and the ONJ group 
and between the bisphosphonate group and the control group. Receiver operating 
characteristic (ROC) curve analysis at T1 and T2 was used to assess the clinical 
performance of the biomarkers. The area under curve (AUC) and cutoff values at 
which the sum of the biomarker sensitivity and specificity was highest (Youden’s J 
statistic) were calculated. The intra-assay coefficient of variability (CVa; analytical 
variability) of each marker was determined as the mean value of duplicated 
measurements. The inter-assay coefficient of variability (CVi; biological variability) 
was determined as the mean change observed at T2 compared with T0 in the control 
group. The least significant change (LSC) at P < 0.05 was determined based on the 
equation: LSC = 2.33 × �(𝐶𝐶𝐶𝐶𝐶𝐶2 + 𝐶𝐶𝐶𝐶𝐶𝐶2)27. The signal to noise ratio was determined 
by dividing the change of each marker in the bisphosphonate group at T2 (signal) with 
the marker’s variability (noise; √𝐶𝐶𝐶𝐶𝐶𝐶2 + 𝐶𝐶𝐶𝐶𝐶𝐶2). The normalized number of 
osteoclasts were compared using analysis of variance with Bonferroni correction. A P 
value of less than 0.05 was considered statistically significant. Statistical analysis was 
carried out using SPSS 20.0 (IBM Corp., Armonk, NY, USA) and MedCalc 12.7.0 
(Medcalc software, Ostend, Belgium). 
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III. Results 
 
1. ONJ determination and histological features 
Of the 36 rats in the bisphosphonate group, 27 rats were histologically 
classified into the ONJ group, and nine rats were classified into the non-ONJ group. 
Representative histologic sections are presented in figure 3. Control group showed 
normal course of healing of extraction socket with newly filled bone and complete 
mucosal coverage. On the other hand, ONJ group showed extensive ulcerative lesion 
accompanied by exposed and necrotic bone with sequestrum and bacterial colonies. 
Also pseudoepitheliomatous-like hyperplasia of epithelium accompanied with 
inflammatory cell infiltration to the connective tissue was observed. Non-ONJ group 
showed mucosal coverage over extraction socket, however the presence of 
inflammatory process and microbial colonies were observed. Also marked decrease of 
bone fill was found compared to control group.   
  13 
(a) 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3. Representative histological features of each group 
(a) Control rat showing normal healing course after post-extraction with complete 
mucosal healing and sufficient bone fill. (HE, X40)  
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 (b) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
   (c) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
(Fig 3. Continued) (b, c) Normal trabecular patterns and bone remodeling are 
observed. Note the cellular lacunae, vascularity, and reversal line. (HE, X100, 200)  
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(d) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
(e) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
(Fig 3. Continued) (d) Non-ONJ rat showing normal mucosal healing, but minimal 
bone fill is observed with the presence of sequestrum and inflammatory cell 
infiltration within connective tissue. (HE, X40), (e) Non-ONJ rat showing abnormal 
bone remodeling patterns showing minimal bone fill from the reversal line. Note 
vital osteocytes and reduced vascularity. (HE, X100) 
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(f) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
(g) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
(Fig 3. Continued) (f) Sequestrum and infiltration of inflammatory cells (HE, 
X100), (g) Detached, hypernucleated, and not-resorbing inactive osteoclasts (HE, 
X400)  
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(h) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
(Fig 3. Continued) (h) Representative ONJ section showing ulcerative mucosa 
with exposed and necrotic bone with osteolysis (HE, X40) 
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(i) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
(j) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
(Fig 3. Continued) (i,j) Histologically determined ONJ section showing necrotic bone 
associated with pseudoepitheliomatous hyperplasia and infiltrates of inflammatory 
cells. Note empty osteocytic lacunae and extensive scalloping of bone edges 
suggestive of interrupted Howship lacunae (HE, X100) 
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(k)  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
(l) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
(Fig 3. Continued) (k) Osteoclasts attempting to resorb zoledronate loaded bone 
showing apoptotic and pyknotic nuclei. (HE, X400), (l) Abnormally osteoclast-poor 
hematopoietic tissue besides bone. (HE, X400) 
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2. Investigation of biomarkers 
The values of all the studied markers are presented in Table 1. CTx, TRACP 
5b, and RANKL were significantly decreased in the bisphosphonate group compared 
to control group at both T1 and T2.  
For analysis of potential biomarkers of ONJ, we analyzed the biomarker 
concentrations over time between the non-ONJ group and the ONJ group. Our data 
demonstrated that the markers which showed significant group difference were 
TRACP 5b and the RANKL/OPG ratio (Figure 4). RM-ANOVA revealed the 
significant lower value of TRACP 5b and RANKL/OPG ratio in ONJ group over time 
compared to non-ONJ group. (P<0.05) These results were consistent at T1 for the 
RANKL/OPG ratio and at T2 for TRACP 5b and the RANKL/OPG ratio (P < 0.05). 
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Table 1. Values of Biomarkers between two groups 
  T0 T1 T2 
CTx (pg/mL) Control 22.86 (10.81) 20.41 (11.27) 22.91 (10.15) 
 Non-ONJ 21.61 (8.35) 10.50 (3.38) * 11.61 (7.48) * 
 ONJ 20.70 (7.90) 10.33 (3.20) * 10.62 (3.54) * 
Glu-OC (μg/L) Control 39.59 (10.96) 42.72 (15.74) 41.28 (10.71) 
 Non-ONJ 41.85 (10.66) 30.46 (11.81) 27.53 (13.69) 
 ONJ 45.22 (14.38) 31.74 (12.74) 30.26 (13.52) 
TRACP 5b  Control 5.07 (1.08) 4.68 (1.26) 5.25 (1.55) 
 Non-ONJ 4.62 (1.12) 2.34 (1.38) * 3.21 (0.71) * 
 ONJ 4.33 (1.21) 2.25 (1.14) * 2.40 (0.76) *† 
RANKL 
(pg/mL) 
Control 
783.64 (141.41) 905.50 (57.46) 853.52 (92.44) 
 Non-ONJ 824.55 (102.84) 693.41 (121.71) * 682.21 (100.60) * 
 ONJ 798.69 (107.99) 613.21 (151.66) * 580.92 (103.91) * 
OPG (pg/mL) Control 611.99 (157.26) 657.71 (99.85) 677.79 (134.96) 
 Non-ONJ 705.76 (129.69) 669.19 (169.62) 669.54 (177.29) 
 ONJ 626.92 (137.34) 749.60 (184.08) 720.88 (145.53) 
RANKL/OPG  Control 1.36 (0.46) 1.41 (0.27) 1.33 (0.40) 
Ratio Non-ONJ 1.19 (0.15) 1.07 (0.19) * 1.08 (0.32) * 
 ONJ 1.33 (0.31) 0.85 (0.24) *† 0.83 (0.20) *† 
Abbreviations; CTx, C-terminal crosslinked telopeptide of type I collagen; Glu-OC, 
Undercarboxylated osteocalcin; TRACP 5b, Tartrate-resistant acid phosphatase isoform 5b; 
RANKL, Receptor activator of nuclear factor-κβ ligand; OPG, Osteoprotegerin  
T0; Baseline, T1; At surgical intervention (6 weeks), T2; At sacrifice (14 weeks) 
Results are shown as mean (SD). 
* indicates significant group difference (P < 0.05) compared to control group at the same time 
point 
† indicates significant group difference (P < 0.05) between Non-ONJ group and ONJ group at 
the same time point 
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(a) 
 
 
 
 
 
 
 
 
 
 
 
 
(b) 
 
 
 
 
 
 
 
 
 
 
 
Figure 4. Trends of biomarkers over time. (a) C-terminal crosslinked telopeptide of 
type I collagen (CTx), (b) Undercarboxylated osteocalcin (Glu-OC) 
T0; Baseline, T1; At surgical intervention (6 weeks), T2; At sacrifice (14 weeks) 
The results are shown as the mean (SE).   
* indicates P < 0.05 between Non-ONJ group versus ONJ-group.   
  23 
(c) 
 
 
 
 
 
 
 
 
 
(d) 
 
 
 
 
(Fig 4. Continued) (c) Tartrate-resistant acid phosphatase isoform 5b (TRACP 5b), 
(d) Receptor activator of nuclear factor-κβ ligand (RANKL) 
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(e) 
 
 
 
 
 
 
 
 
 
(f) 
 
 
 
 
 
 
(Fig 4. Continued) (e) Osteoprotegerin (OPG), (f) RANKL/OPG Ratio 
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3. Clinical performance of biomarkers 
To assess the clinical performance of TRACP 5b and the RANKL/OPG ratio 
as a biomarker for ONJ, we constructed ROC curves at T1 and T2 (Figure 5). For 
TRACP 5b at T2, the AUC was 0.807 (95% confidence interval [CI], 0.641–0.919; P 
< 0.001), and the cutoff value with both maximal sensitivity and specificity was 3.09 
U/L or less. At this cutoff, the sensitivity and specificity of TRACP 5b for the 
diagnosis of ONJ were 88.9% and 66.7%, respectively. For the RANKL/OPG ratio at 
T1, the AUC was 0.776 (95% CI, 0.606–897; P < 0.001). The AUC at T2 was 0.765 
(95% CI, 0.595–0.890; P = 0.002), and the cutoff value was 0.88 or less (sensitivity, 
77.8%; specificity, 62.9%).  
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Figure 5. Receiver operating characteristic (ROC) curves of serum TRACP 5b and 
RANKL/OPG ratio  
T1: TRACP 5b, AUC (95% CI) = 0.519 (0.346-0.688), P > 0.05; RANKL/OPG Ratio, 
AUC (95% CI) = 0.776 (0.606-0.897), P < 0.001 
T2: TRACP 5b, AUC (95% CI) = 0.807 (0.641-0.919), P < 0.001; RANKL/OPG 
Ratio, AUC (95% CI) = 0.765 (0.595-0.890), P = 0.002  
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Individual percent changes (T2 – T0) of TRACP 5b and the RANKL/OPG 
ratio are shown in Figure 6. TRACP 5b had a lower LSC (29.6%) with lower intra-
assay CV (6.32%) and inter-assay CV (11.20%) compared to those of the 
RANKL/OPG ratio (intra-assay CV, 8.14%; inter-assay CV, 14.76%; LSC, 39.27%). 
TRACP 5b had a higher signal-to-noise ratio (2.76) than the RANKL/OPG ratio 
(1.62). 
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 Figure 6. Individual percent changes of TRACP 5b and RANKL/OPG ratio  
TRACP Intra-assay CV: 6.32% / Inter-assay CV: 11.20% / LSC: 29.96% 
RANKL/OPG Ratio Intra-assay CV: 8.14% / Inter-assay CV: 14.76% / LSC: 
39.27% 
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4. Histomorphometric analysis 
In histomorphometric analysis, there was no group difference in T.Ar, B.Ar 
and B.Ar/T.Ar. It was evident that N.Oc of ONJ group (4.96 ± 1.83) were significantly 
lower than that of control (11.00 ± 2.52) and non-ONJ group (7.78 ± 1.30). (P < 0.05) 
Normalized indices, N.Oc/T.Ar and N.Oc/B.Ar demonstrated significantly lower 
number of osteoclasts in ONJ group than non-ONJ group. (P < 0.05; Fig. 7)  
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 Figure 7. Histomorphometric analysis showing significantly lower number of 
osteoclasts in ONJ-group 
* indicates P < 0.05 versus control, † indicates P < 0.05 between ONJ and Non-ONJ 
group 
Abbreviations; T.Ar, tissue area; B.Ar, bone area; N.Oc, number of osteoclasts  
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IV. Discussion 
This study was conducted to identify novel potential biomarkers of ONJ 
using several bone markers, including serum CTx, Glu-OC, TRACP 5b, RANKL, and 
OPG in an animal model. The results showed that serum TRACP 5b and the 
RANKL/OPG ratio were possible biomarkers for ONJ. Because no consensus has 
been reached on with the accuracy of currently proposed candidate biomarkers, this 
thesis was important in that it investigated possible biomarkers based on the 
pathogenesis of ONJ. Additionally, biomarkers may reflect dynamic conditions in the 
bone milieu that cannot be observed using conventional clinical or radiologic 
modalities; therefore, these biomarkers will function as useful tools for the diagnosis, 
prognosis, and risk prediction of ONJ. Furthermore, elucidation of the molecular roles 
of these biomarkers may provide insights into the direction of future ONJ research. 
Rats in this study were designed to approximate the cumulative treatment 
regimen of cancer patients who received a single IV administration of zoledronic acid 
every 3 to 4 weeks (12 to 16 doses per year) during relatively short 14 weeks 
experimental period24. With consideration of rapid healing of rodents, which takes 
one-third of the time as compared to human28, dosing frequency was determined as 
once a week. Although definitive pharmacokinetics of zoledronate in rodents are not 
fully understood, crucial features - uptake clearance of BPs by bone, renal clearance, 
and plasma protein binding characteristics - of rodents have been reported to be 
similar or slightly higher than those of human29,30. Moreover, a recent study reported 
that single bolus injection develop more ONJ lesion compared to repeated fractional 
dosing in spite of the equivalent cumulative dose31. Given the lower Cmax (maximum 
serum concentration that a drug achieves in body after the drug has been administered) 
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and AUC (total drug exposure over time) of subcutaneous injection30, the rats in this 
study received a subcutaneous zoledronate dose 3 times higher as compared to the 
standard IV human regimen.  
As a result, 75% of zoledronate-injected rats developed ONJ lesion, which is 
much higher compared to the incidence of 0.8-12% of IV bisphosphonate-treated 
human patients32. More frequent dosing cycle and higher single dose are thought to 
bring higher total drug exposure to calcified tissue, followed by dose-dependent 
increase of ONJ development33,34. Regarding the unique pharmacologic characteristics 
of bisphosphonates – very low absorption rate of <1%, rapid initial uptake clearance, 
and very low drug plasma concentrations, direct influence of bisphosphonates 
concentration on serum biomarkers seems minimal30. However, it cannot be excluded 
that highly deposited bisphosphonates possibly amplified the changes of biomarker 
over time. Variability between species should be considered as well for interpreting 
results of this study. Properly designed clinical trials are urgently needed to validate 
the utility of biomarkers for BRONJ. 
Serum TRACP 5b has been a promising marker in the fields of bone disease, 
especially for its exclusive specificity from osteoclast and unique characteristics as a 
biomarker; low diurnal variability, stable storage, being not affected by feeding and 
the existence of renal or hepatic failure27,35. Clinically, the diagnostic and prognostic 
efficacies of TRACP 5b have progressively been validated in osteoporosis, bone 
metastatic cancers, chronic renal failure, and other metabolic and pathologic bone 
diseases17,36. Because TRACP 5b reflects the osteoclast number16,17, and osteoclast 
number rather than osteoclastic activity is associated with bone remodeling13,14,18,19, 
the use of TRACP 5b for the assessment of oversuppressed bone remodeling seems 
biologically feasible. In this study, ONJ group exhibited significantly lower levels of 
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serum TRACP 5b than non-ONJ group. (Fig. 3) This, the low concentration of 
TRACP 5b may indicate abnormal suppression of bone remodeling, which can lead to 
the development of ONJ.  
RANK/RANKL/OPG is a well-known system that is capable of regulating 
most aspects of osteoclast function, including proliferation, differentiation, activation, 
and apoptosis20. Abnormalities in this system have been implicated in the pathogenesis 
of various bone diseases21. Regarding circulating OPG and RANKL, the diagnostic 
and prognostic applications of the serum RANKL/OPG ratio in multiple myeloma and 
bone metastatic diseases showed promise for reflecting abnormal bone remodeling22,23. 
Interestingly, a prospective study of 906 patients reported significantly lower serum 
levels of RANKL as an independent predictor of non-traumatic fracture with a relative 
risk of 1037. Also, several in vitro and clinical studies revealed a direct influence of 
bisphosphonates on mRNA expression and serum level of RANKL and OPG23,38-41. 
Therefore RANKL may have an important role in bone turnover, which can be 
similarly interpreted to ONJ. However, several limitations, such as the relatively low 
bone-specificity and questionable capacity for reflecting the localized bone 
environment, should be resolved in order to determine whether RANKL has relevant 
clinical applications23. 
There have been increasing evidences that inactive mature osteoclasts play an 
important role in mediating bone remodeling through coupling process15,18,42,43. 
Coupling factors were demonstrated to be secreted normally in relatively inactive 
osteoclasts, and correlated to osteoclast number rather than activity15,19. These findings 
provide valuable insights into the biological interpretation of the results of this study. 
The significantly higher TRACP 5b and RANKL/OPG ratio in non-ONJ group 
without difference of bone resorption as expressed by CTx imply the role of inactive 
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osteoclasts for the osteoclast-mediated bone remodeling activity regardless of 
resorptive activity. Subsequently, these biomarkers could facilitate to reflect 
oversuppression of bone associated with BRONJ. Besides, this interpretation is 
corroborated by the biological performance of TRACP 5b, which is relatively more 
investigated; non-resorbing inactive osteoclasts were also able to secrete TRACP 5b 
albeit at a slightly lower level than their resorbing counterparts44, and TRAP release 
occurs at an earlier stage of osteoclastogenesis and is not restricted to the bone 
resorption by mature osteoclasts45. 
In this study, serum TRACP 5b levels were significantly reduced in the ONJ 
group at the time of sacrifice, while the serum RANKL/OPG ratio was significantly 
reduced at both the time of sacrifice and the time of surgical intervention. Clinically, 
the time of sacrifice may be interpreted as having diagnostic capability, while the time 
of surgical intervention can be interpreted at having risk predictive ability. Because the 
current diagnostic criteria for ONJ are based only on ambiguous clinical information11, 
diagnosis of ONJ through biomarkers may allow the establishment of clear diagnostic 
criteria and may enable the disease to be standardized. On the other hand, markers that 
are thought to have more clinical significance may be able to be applied for 
assessment of ONJ risk. When dental intervention is needed in patients receiving 
bisphosphonates, biomarkers that can determine the risk of ONJ development would 
be useful for the choice of treatment modalities by physicians and dentists. 
Considering that the term biomarker generally connote the predictability of disease 
progress, the significance of serum TRACP 5b only at the time of surgical intervention 
alludes the limited applicability of results of this study. Although the serum 
RANKL/OPG ratio differed significantly at the time of surgical intervention in this 
thesis, further validation in human studies is required.  
  35 
Several clinical and in vivo studies have reported an association between 
ONJ development and the dose-dependent accumulation of bisphosphonates in the 
jaw31,46. Nevertheless, the various responses to bisphosphonates under similar 
conditions such as in animal studies may stem from different individual 
pharmacological responses47,48. This hypothesis is associated with another ONJ 
hypothesis: role of pharmacogenetic susceptibility49. It can be inferred that individuals 
who respond to bisphosphonates well may be at higher risk of ONJ development. This 
is consistent with the results of this thesis; lower levels of TRACP 5b and lower 
RANKL/OPG ratios were observed in the ONJ group. Further pharmacogenetic 
researches, such as determination of individual genetic profiles and pharmacological 
responses, are required.  
In conclusion, our data demonstrated that lower serum TRACP 5b levels and 
reduced RANKL/OPG ratios were associated with ONJ. These findings are consistent 
with both the current hypothesis of ONJ and the molecular roles of biomarkers. After 
validation studies with human ONJ patients, these biomarkers may provide crucial 
tools for diagnosis and risk prediction of ONJ and insights into future directions for 
ONJ research. 
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Abstract (In Korean) 
 
비스포스포네이트 관련 악골 괴사증의 바이오마커 탐지 
김  진  우 
연세대학교 대학원 치의학과 
지도 교수   차 인 호 
 
비스포스포네이트 사용과 관련된 심각한 합병증인 악골 괴사증의 진단과 
예후 예측, 그리고 위험도 평가를 위해 여러 골 마커들이 제안되어 왔으나 
많은 논란이 있어왔다. 본 연구의 목적은 동물 모델을 통해 
비스포스포네이트 관련 악골 괴사증의 바이오마커를 발굴하기 위함이다.  
총 48 마리의 Sparague-Dawley 쥐를 한 주에 한번씩 zoledronic 
acid 를 정맥 투여한 비스포스포네이트 그룹 (n=36)과 생리 식염수를 
투여한 대조군 (n=12)으로 무작위 분류하였다. 투여 6 주 후, 외과적 
처치로써 하악 좌측 제 1,2,3 대구치의 발거가 시행되었으며 그 후 8 주 
동안 추가 투여를 시행하고 희생하였다. CTx, Glu-OC, TRACP 5b, RANKL, 
OPG 등의 바이오마커를 실험 시작 시 (T0), 외과적 처치 시 (T1), 희생 시 
(T2)에 측정하였으며, 비스포스포네이트 그룹의 쥐들은 조직학적인 분석을 
통하여 골괴사 발생 그룹 (ONJ)과 미발생 그룹 (non-ONJ) 그룹으로 
분류하였다. 또한 파골세포의 정량화를 위한 조직계측학적 분석이 
시행되었다.  
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반복측정 분산분석 결과, TRACP 5b 및 RANKL/OPG 비율이 시간에 따라 
ONJ 그룹에서 non-ONJ 에 비해 유의하게 감소하였다 (P <0.05). T2 
시점에서 TRACP 5b 의 곡선하면적 (area under curve)은 0.807 (컷 
오프에서 민감도: 88.9%, 특이도: 66.7%) 이었으며, RANKL/OPG 비율은 
0.765 (컷 오프에서 민감도: 77.8%, 특이도 62.9%)로써 만족스러운 
진단학적인 가치를 보였다. TRACP 5b 는 RANKL/OPG 비율에 비하여 더 
낮은 최소 유의 변화 (least significant change; 29.6%) 및 더 높은 
signal-to-noise ratio (2.76)을 나타내어, TRACP 5b 가 더 높은 마커 
정밀도를 나타내었다. 조직계측학적 분석 결과 ONJ 그룹은 non-ONJ 
그룹에 비교하여 유의하게 파골세포 수가 더 적었다. (P <0.05) 
위 연구 결과를 종합하여 볼 때, TRACP 5b 및 RANKL/OPG 비율이 
비스포스포네이트 관련 악골 괴사증의 바이오마커로 사용될 수 있을 
것이라 사료된다. 본 연구 결과를 뒷받침하기 위한 악골 괴사증이 발병한 
인간 환자를 대상으로 임상 연구가 필요할 것으로 사료된다.  
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핵심되는 말: Bisphosphonates; Osteonecrosis of Jaw; Biomarker; 
Tartrate-resistant acid phosphatase; receptor activator of nuclear factor-
κβ ligand 
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